Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。